FAROPENEM

Possibly Marketed Outside US

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C12H15NO5S
Molecular Weight	285.316
Optical Activity	( + )
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

C[C@@H](O)[C@@H]1[C@H]2SC([C@H]3CCCO3)=C(N2C1=O)C(O)=O

InChI

InChIKey=HGGAKXAHAYOLDJ-FHZUQPTBSA-N

InChI=1S/C12H15NO5S/c1-5(14)7-10(15)13-8(12(16)17)9(19-11(7)13)6-3-2-4-18-6/h5-7,11,14H,2-4H2,1H3,(H,16,17)/t5-,6-,7+,11-/m1/s1

HIDE SMILES / InChI

Description

Faropenem is a unique antimicrobial penem being developed for oral administration. It markets it in two forms: faropenem sodium and faropenem medoxomil. The high binding affinities of faropenem to penicillin-binding proteins from gram-negative and gram-positive bacteria are mirrored by its pronounced and concentration-dependent bactericidal effect. It is usually used to treat a wide range of infections such as skin, respiratory and otorhinologic infections. The most commonly reported adverse reactions include diarrhea, abdominal pain, loose stool, rash and nausea. The FDA refused to approve faropenem – the applicant have to conduct new studies and clinical trials to prove the drug treats community-acquired pneumonia, bacterial sinusitis, chronic bronchitis, and skin infections.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Bacterial penicillin-binding protein 234	Inhibitor 8,504

Conditions

Condition	Modality	Highest Phase	Product
Chronic bronchitis 52	Curative	Approved 8,583	Farom
Community-acquired pneumonia 47	Curative	Approved 8,583	Farom
Acute bacterial sinusitis 26	Curative	Approved 8,583	Farom
Skin infections 59	Curative	Approved 8,583	Farom

C_max

Value	Dose	Analyte	Population
1.32 μg/mL	5 mg single, oral	FAROPENEM plasma	Homo sapiens
2.08 μg/mL	10 mg single, oral	FAROPENEM plasma	Homo sapiens
2.36 μg/mL	150 mg single, oral	FAROPENEM plasma	Homo sapiens
6.24 μg/mL	300 mg single, oral	FAROPENEM plasma	Homo sapiens
7.37 μg/mL	600 mg single, oral	FAROPENEM plasma	Homo sapiens
1.9 μg/mL	200 mg 3 times / day multiple, oral	FAROPENEM plasma	Homo sapiens
2.02 μg/mL	200 mg 3 times / day multiple, oral	FAROPENEM plasma	Homo sapiens
1.89 μg/mL	200 mg 3 times / day multiple, oral	FAROPENEM plasma	Homo sapiens
6.24 μg/mL	300 mg single, oral	FAROPENEM plasma	Homo sapiens
4.25 μg/mL	300 mg single, oral	FAROPENEM plasma	Homo sapiens
3.49 μg/mL	300 mg single, oral	FAROPENEM plasma	Homo sapiens
4.25 μg/mL	300 mg single, oral	FAROPENEM plasma	Homo sapiens

AUC

Value	Dose	Analyte	Population
4.1 μg × h/mL	5 mg single, oral	FAROPENEM plasma	Homo sapiens
5.89 μg × h/mL	10 mg single, oral	FAROPENEM plasma	Homo sapiens
3.95 μg × h/mL	150 mg single, oral	FAROPENEM plasma	Homo sapiens
11.73 μg × h/mL	300 mg single, oral	FAROPENEM plasma	Homo sapiens
19.59 μg × h/mL	600 mg single, oral	FAROPENEM plasma	Homo sapiens
4.18 μg × h/mL	200 mg 3 times / day multiple, oral	FAROPENEM plasma	Homo sapiens
4.34 μg × h/mL	200 mg 3 times / day multiple, oral	FAROPENEM plasma	Homo sapiens
4.14 μg × h/mL	200 mg 3 times / day multiple, oral	FAROPENEM plasma	Homo sapiens
11.73 μg × h/mL	300 mg single, oral	FAROPENEM plasma	Homo sapiens
9.75 μg × h/mL	300 mg single, oral	FAROPENEM plasma	Homo sapiens
16.49 μg × h/mL	300 mg single, oral	FAROPENEM plasma	Homo sapiens
9.75 μg × h/mL	300 mg single, oral	FAROPENEM plasma	Homo sapiens

T_1/2

Value	Dose	Analyte	Population
1.66 h	5 mg single, oral	FAROPENEM plasma	Homo sapiens
1.14 h	10 mg single, oral	FAROPENEM plasma	Homo sapiens
0.76 h	150 mg single, oral	FAROPENEM plasma	Homo sapiens
0.85 h	300 mg single, oral	FAROPENEM plasma	Homo sapiens
1.08 h	600 mg single, oral	FAROPENEM plasma	Homo sapiens
0.96 h	200 mg 3 times / day multiple, oral	FAROPENEM plasma	Homo sapiens
0.89 h	200 mg 3 times / day multiple, oral	FAROPENEM plasma	Homo sapiens
0.93 h	200 mg 3 times / day multiple, oral	FAROPENEM plasma	Homo sapiens
0.85 h	300 mg single, oral	FAROPENEM plasma	Homo sapiens
1.01 h	300 mg single, oral	FAROPENEM plasma	Homo sapiens
1.61 h	300 mg single, oral	FAROPENEM plasma	Homo sapiens
1.01 h	300 mg single, oral	FAROPENEM plasma	Homo sapiens

F_unbound

Value	Dose	Co-administered	Analyte	Population
9.3%			FAROPENEM serum	Homo sapiens

Doses

Show entries

Dose	Population	Adverse events
300 mg 2 times / day multiple, oral Recommended	unhealthy, ADULT	Disc. AE: Diarrhea, Vomiting... Other AEs: Nausea...

Showing 1 to 1 of 1 entries

Previous1Next

AEs

Show entries

AE	Significance	Dose	Population
Nausea		300 mg 2 times / day multiple, oral Recommended	unhealthy, ADULT
Diarrhea	Disc. AE	300 mg 2 times / day multiple, oral Recommended	unhealthy, ADULT
Vomiting	Disc. AE	300 mg 2 times / day multiple, oral Recommended	unhealthy, ADULT

Showing 1 to 3 of 3 entries

Previous1Next

PubMed

Show entries

Title	Date	PubMed
In vitro activity of faropenem and 21 other compounds against 385 different genetically characterized isolates of antibiotic-resistant Streptococcus pneumoniae.	2001 Jul	11418531
[Triple therapy with faropenem, proton pump inhibitor (PPI), and amoxicillin for clarithromycin-resistant H. pylori eradication].	2002 Feb	11979826
Effect of protein binding on the in vitro activity and pharmacodynamics of faropenem.	2002 Oct	12356797
Antimicrobial susceptibility of major pathogens of orofacial odontogenic infections to 11 beta-lactam antibiotics.	2002 Oct	12354209
Comparative in vitro activity of faropenem and 11 other antimicrobial agents against 405 aerobic and anaerobic pathogens isolated from skin and soft tissue infections from animal and human bites.	2002 Sep	12205068

Showing 1 to 5 of 19 entries

Previous1 2 3 4Next

Patents

Sample Use Guides

In Vivo Use Guide

150 - 300 mg three times a day

Route of Administration: Oral

In Vitro Use Guide

Exposure of S. aureus to faropenem at minimum inhibitory concentrations (MICs) of 1/8 or 1/4 resulted in irregular septum formation. At 1x MIC or higher, a larger number of lysed cells were observed. Exposure of E. coli to 1/8x MIC or 1/4x MIC also induced changes in cellular shape; the normal rod-shaped form changed to a spherical form in a time-dependent manner. After exposure of E. coli to 1x MIC for 2 h, bulging-shaped E. coli cells were observed and after 4 h of exposure cell lysis was demonstrated. In the presence of 4x MIC, spheroplast-like forms and cell lysis were observed.

Show entries

Name

Type

Language

FAROPENEM [MI]

Preferred Name

English

FAROPENEM

Official Name

English

faropenem [INN]

Common Name

English

4-THIA-1-AZABICYCLO(3.2.0)HEPT-2-ENE-2-CARBOXYLIC ACID, 6-((1R)-1-HYDROXYETHYL)-7-OXO-3-((2R)-TETRAHYDRO-2-FURANYL)-,(5R,6S)

Common Name

English

FROPENEM

Common Name

English

Showing 1 to 5 of 7 entries

Previous1 2Next

Show entries

Classification Tree

Code System

Code

Other cephalosporins and penems

WHO-ATC

J01DI03

Antibiotic

NCI_THESAURUS

C260

Other cephalosporins and penems

WHO-VATC

QJ01DI03

Showing 1 to 3 of 3 entries

Previous1Next

Show entries

Code System

Code

Type

Description

DRUG CENTRAL

1131

PRIMARY

SMS_ID

100000081763

PRIMARY

PUBCHEM

65894

PRIMARY

FDA UNII

F52Y83BGH3

PRIMARY

EVMPD

SUB07512MIG

PRIMARY

Showing 1 to 5 of 15 entries

Previous1 2 3Next

ACTIVE MOIETY


					F52Y83BGH3

FAROPENEM

SALT/SOLVATE (PARENT)


					N39L5ALZ3M

FAROPENEM SODIUM HEMIPENTAHYDRATE

SMILES

InChI

Originator

Approval Year

Targets

Conditions

Cmax

AUC

T1/2

Funbound

Doses

AEs

PubMed

Patents

Sample Use Guides

C_max

T_1/2

F_unbound